Rating Change
Wedbush reiterated its Neutral rating on Vera Therapeutics, Inc. (NASDAQ:VERA) on August 17, 2026.
Wedbush reiterated its Neutral rating on Vera Therapeutics, Inc. (NASDAQ:VERA) on August 17, 2026.

At publication ·
Vera Therapeutics, Inc. (NASDAQ:VERA) · reiterate
At a glance
Wedbush reiterated its Neutral rating on Vera Therapeutics, Inc. (NASDAQ:VERA) on August 17, 2026.
Vera Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $31.63 with a market capitalization of $2.9B.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Vera Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 17, 2026 | Wedbush | Neutral | N/A |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 11, 2026 | Wedbush | Neutral | N/A |
| Jul 08, 2026 | TD Cowen | Buy | N/A |
| Jul 08, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View VERA Stock Page
A rating of Neutral from Wedbush reflects the analyst's outlook on Vera Therapeutics, Inc. (NASDAQ:VERA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the VERA forecast page.
Current market data
NASDAQ · VERA
$32.28
Up: +$1.02 · +3.25%
Live quote updated
Keep reading
analyst ·
analyst ·
earnings ·
earnings ·